{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:35:53Z","timestamp":1790908553572,"version":"4.1.0"},"reference-count":62,"publisher":"Harborside Press, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Over the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value. Second-generation TKIs may be the best frontline strategy when treatment-free remission is the goal. Recent studies have shown maintained efficacy and reduced toxicity when TKIs are used at reduced dosing. Reduced-dose schedules of second-generation TKIs (which are less toxic and induce faster deep molecular responses) may render generic second-generation TKIs a more attractive treatment option. Adjusting the dose of TKI in the presence of mild-to-moderate, or even severe but reversible, adverse events may be preferable to switching to a different TKI. The selection of second-line and beyond therapies depends on the evolving patterns observed with frontline treatment. Dose-adjusted ponatinib schedules have demonstrated improved efficacy and safety in patients resistant to second-generation TKIs or those with T315I-mutated disease. For asciminib, longer-term follow-up is needed to better evaluate its safety and efficacy compared with ponatinib. Allogeneic stem cell transplantation represents a valid alternative to newer-generation TKIs, with a better treatment value when TKIs are priced at &gt;$40,000\/year.<\/jats:p>","DOI":"10.6004\/jnccn.2023.7116","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T20:29:39Z","timestamp":1708720179000},"source":"Crossref","is-referenced-by-count":21,"title":["Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors"],"prefix":"10.6004","volume":"22","author":[{"given":"Fadi G.","family":"Haddad","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Harrison\u2019s Principles of Internal Medicine, 21e","article-title":"Chronic myeloid leukemia","author":"Kantarjian H","year":"2022","unstructured":"Kantarjian H, Jabbour E, Cortes J. Chronic myeloid leukemia. In: Loscalzo J, Fauci A, Kasper D, et al, eds. Harrison\u2019s Principles of Internal Medicine, 21e. McGraw-Hill Education; 2022."},{"key":"B2","series-title":"Lancet Haematol","first-page":"e186","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki K","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S,  Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2015;2:e186\u2013193."},{"key":"B3","series-title":"Am J Hematol","first-page":"1236","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour E","year":"2022","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 2022;97:1236\u20131256."},{"key":"B4","series-title":"N Engl J Med","first-page":"917","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F,  Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376:917\u2013927."},{"key":"B5","series-title":"N Engl J Med","first-page":"2251","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio G","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S,  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251\u20132259."},{"key":"B6","series-title":"N Engl J Med","first-page":"994","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien SG","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA,  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994\u20131004."},{"key":"B7","series-title":"N Engl J Med","first-page":"2260","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian H","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A,  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260\u20132270."},{"key":"B8","series-title":"J Clin Oncol","first-page":"231","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW,  Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 2018;36:231\u2013237."},{"key":"B9","series-title":"N Engl J Med","first-page":"1783","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes JE","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J,  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783\u20131796."},{"key":"B10","series-title":"Blood","first-page":"2031","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a D","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C,  A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 2021;138:2031\u20132041."},{"key":"B11","series-title":"Magic Cancer Bullet: How a Tiny Orange Pill is Rewriting Medical History","author":"Vasella D","year":"2003","unstructured":"Vasella D, Slater R. Magic Cancer Bullet: How a Tiny Orange Pill is Rewriting Medical History. Harper Business; 2003."},{"key":"B12","series-title":"Cancer","first-page":"3123","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang X","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012;118:3123\u20133127."},{"key":"B13","series-title":"Blood","first-page":"4439","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","author":"Abboud C","year":"2013","unstructured":"Abboud C, Bermin E, Cohen A,  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439\u20134442."},{"key":"B14","series-title":"Blood","first-page":"1398","article-title":"Strategies that delay or prevent the timely availability of affordable generic drugs in the United States","volume":"127","author":"Jones GH","year":"2016","unstructured":"Jones GH, Carrier MA, Silver RT,  Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood 2016;127:1398\u20131402."},{"key":"B15","series-title":"Cancer Lett","first-page":"7","article-title":"Why drugs cost too much and how prices can be brought down","volume":"39","author":"Kantarjian H","year":"2013","unstructured":"Kantarjian H. Why drugs cost too much and how prices can be brought down. Cancer Lett 2013;39:7\u201311."},{"key":"B16","series-title":"Cancer","first-page":"1292","article-title":"High cancer drug prices 4 years later\u2014progress and prospects","volume":"123","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Patel Y. High cancer drug prices 4 years later\u2014progress and prospects. Cancer 2017;123:1292\u20131297."},{"key":"B17","series-title":"Lancet Haematol","first-page":"e854","article-title":"The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post- marketing research on the treatment of chronic myeloid leukaemia in the USA","volume":"9","author":"Kantarjian H","year":"2022","unstructured":"Kantarjian H, Paul S, Thakkar J,  The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post- marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol 2022;9:e854\u2013861."},{"key":"B18","series-title":"Mayo Clin Proc","first-page":"500","article-title":"Why are cancer drugs so expensive in the United States, and what are the solutions?","volume":"90","author":"Kantarjian H","year":"2015","unstructured":"Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc 2015;90:500\u2013504."},{"key":"B19","series-title":"J Oncol Pract","first-page":"e208","article-title":"High cancer drug prices in the United States: reasons and proposed solutions","volume":"10","author":"Kantarjian H","year":"2014","unstructured":"Kantarjian H, Steensma D, Rius Sanjuan J,  High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract 2014;10:e208\u2013211."},{"key":"B20","series-title":"Lancet Haematol","first-page":"e860","article-title":"Revisiting six established practices in the treatment of chronic myeloid leukaemia","volume":"10","author":"Kantarjian H","year":"2023","unstructured":"Kantarjian H, Welch MA, Jabbour E. Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol 2023;10:e860\u2013864."},{"key":"B21","series-title":"Lancet Haematol","first-page":"e398","article-title":"Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study","volume":"6","author":"Shih YT","year":"2019","unstructured":"Shih YT, Cortes JE, Kantarjian H. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol 2019;6:e398\u2013408."},{"key":"B22","series-title":"Cancer Lett","first-page":"4","article-title":"The Trump administration \u201cAmerican Patients First\u201d plan to reduce drug prices\u2014are American cancer patients first?","volume":"44","author":"Kantarjian H","year":"2018","unstructured":"Kantarjian H, Welch MA. The Trump administration \u201cAmerican Patients First\u201d plan to reduce drug prices\u2014are American cancer patients first? Cancer Lett 2018;44:4\u201311."},{"key":"B23","series-title":"Am J Hematol","first-page":"1444","article-title":"The \u201cAmerican (cancer) patients first\u201d plan to reduce drug prices\u2014a critical assessment","volume":"93","author":"Kantarjian H","year":"2018","unstructured":"Kantarjian H, Light DW, Ho V. The \u201cAmerican (cancer) patients first\u201d plan to reduce drug prices\u2014a critical assessment. Am J Hematol 2018;93:1444\u20131450."},{"key":"B24","series-title":"J Oncol Pract","first-page":"352","article-title":"Journey of generic imatinib: a case study in oncology drug pricing","volume":"13","author":"Chen CT","year":"2017","unstructured":"Chen CT, Kesselheim AS. Journey of generic imatinib: a case study in oncology drug pricing. J Oncol Pract 2017;13:352\u2013355."},{"key":"B25","series-title":"Am J Hematol","first-page":"856","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad FG","year":"2022","unstructured":"Haddad FG, Sasaki K, Issa GC,  Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 2022;97:856\u2013864."},{"key":"B26","series-title":"Lancet Oncol","first-page":"747","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele S","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J,  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 2018;19:747\u2013757."},{"key":"B27","series-title":"Blood Cancer J","first-page":"58","article-title":"Management of chronic myeloid leukemia in 2023 - common ground and common sense","volume":"13","author":"Senapati J","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC,  Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J 2023;13:58."},{"key":"B28","series-title":"Cancer","first-page":"3805","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy\u2014the Surveillance, Epidemiology, and End Results database, 2000\u20132019","volume":"129","author":"Sasaki K","year":"2023","unstructured":"Sasaki K, Haddad FG, Short NJ,  Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy\u2014the Surveillance, Epidemiology, and End Results database, 2000\u20132019. Cancer 2023;129:3805\u20133814."},{"key":"B29","series-title":"Cancer","first-page":"67","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi K","year":"2020","unstructured":"Naqvi K, Jabbour E, Skinner J,  Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2020;126:67\u201375."},{"key":"B30","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"742","article-title":"Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results","volume":"23","author":"Gener-Ricos G","year":"2023","unstructured":"Gener-Ricos G, Haddad FG, Sasaki K,  Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results. Clin Lymphoma Myeloma Leuk 2023;23:742\u2013748."},{"key":"B31","series-title":"Am J Hematol","first-page":"1413","article-title":"Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis","volume":"97","author":"Jabbour E","year":"2022","unstructured":"Jabbour E, Sasaki K, Haddad FG,  Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis. Am J Hematol 2022;97:1413\u20131418."},{"key":"B32","series-title":"Lancet Haematol","first-page":"e902","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai K","year":"2021","unstructured":"Murai K, Ureshino H, Kumagai T,  Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol 2021;8:e902\u2013911."},{"key":"B33","series-title":"Blood","article-title":"Efficacy and safety following dose reduction of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia: analysis of the phase 3 BFORE trial","volume":"132","author":"Brummendorf TH","year":"2018","unstructured":"Brummendorf TH, Gambacorti-Passerini C, Hochhaus A,  Efficacy and safety following dose reduction of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia: analysis of the phase 3 BFORE trial. Blood 2018;132(Suppl 1):Abstract 632."},{"key":"B34","series-title":"HemaSphere","article-title":"Bosutinib dose optimization in the second-line treatment of elderly CML patients: extended 3-year follow-up and final results of the best study","volume":"6","author":"Castagnetti F","year":"2022","unstructured":"Castagnetti F, Bocchia M, Abruzzese E,  Bosutinib dose optimization in the second-line treatment of elderly CML patients: extended 3-year follow-up and final results of the best study. HemaSphere 2022;6:Abstract P698."},{"key":"B35","series-title":"Lancet Haematol","first-page":"e310","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark RE","year":"2017","unstructured":"Clark RE, Polydoros F, Apperley JF,  De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol 2017;4:e310\u2013316."},{"key":"B36","series-title":"Br J Haematol","first-page":"346","article-title":"TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia","volume":"193","author":"Claudiani S","year":"2021","unstructured":"Claudiani S, Apperley JF, Szydlo R,  TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol 2021;193:346\u2013355."},{"key":"B37","series-title":"J Hematol Oncol","first-page":"143","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Apperley JF, DeAngelo DJ,  Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol 2018;11:143."},{"key":"B38","series-title":"Blood","article-title":"Long-term results from the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib","volume":"142","author":"Cortes J","year":"2023","unstructured":"Cortes J, Deininger M, Lomaia E,  Long-term results from the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib. Blood 2023;142(Suppl 1):Abstract 3164."},{"key":"B39","series-title":"Am J Hematol","first-page":"1419","article-title":"Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia","volume":"97","author":"Kantarjian H","year":"2022","unstructured":"Kantarjian H, Jabbour E, Deininger M,  Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol 2022;97:1419\u20131426."},{"key":"B40","series-title":"Blood Adv","first-page":"802","article-title":"The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia","volume":"1","author":"Fox LC","year":"2017","unstructured":"Fox LC, Cummins KD, Costello B,  The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Adv 2017;1:802\u2013811."},{"key":"B41","series-title":"J Clin Oncol","first-page":"2333","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian H,  Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 2016;34:2333\u20132340."},{"key":"B42","series-title":"Leukemia","first-page":"440","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian H","year":"2021","unstructured":"Kantarjian H, Hughes TP, Larson RA,  Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021;35:440\u2013453."},{"key":"B43","series-title":"Expert Rev Clin Pharmacol","first-page":"445","article-title":"Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies","volume":"14","author":"Wang Z","year":"2021","unstructured":"Wang Z, Jiang L, Yan H,  Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. Expert Rev Clin Pharmacol 2021;14:445\u2013456."},{"key":"B44","series-title":"Ann Oncol","first-page":"578","article-title":"Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"29","author":"Khoury HJ","year":"2018","unstructured":"Khoury HJ, Gambacorti-Passerini C, Br\u00fcmmendorf TH. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Ann Oncol 2018;29:578\u2013587."},{"key":"B45","series-title":"Blood","first-page":"1309","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian H","year":"2014","unstructured":"Kantarjian H, Cortes JE, Kim DW,  Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014;123:1309\u20131318."},{"key":"B46","series-title":"Leukemia","first-page":"2398","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann R","year":"2017","unstructured":"Hehlmann R, Lauseker M, Saussele S,  Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 2017;31:2398\u20132406."},{"key":"B47","series-title":"Leukemia","first-page":"2231","article-title":"Survival with chronic myeloid leukaemia after failing milestones","volume":"37","author":"Lauseker M","year":"2023","unstructured":"Lauseker M, Hehlmann R, Hochhaus A,  Survival with chronic myeloid leukaemia after failing milestones. Leukemia 2023;37:2231\u20132236."},{"key":"B48","series-title":"Leukemia","first-page":"2324","article-title":"What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia","volume":"37","author":"Kantarjian H","year":"2023","unstructured":"Kantarjian H. What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia. Leukemia 2023;37:2324\u20132325."},{"key":"B49","series-title":"HemaSphere","article-title":"Qu\u00e9bec CML Research Group analysis of treatment patterns in chronic myelogenous leukemia: switching is driven by intolerance and similar across tyrosine kinase inhibitors and lines of treatment","volume":"6","author":"Busque L","year":"2022","unstructured":"Busque L, Harnois M, Szuber N,  Qu\u00e9bec CML Research Group analysis of treatment patterns in chronic myelogenous leukemia: switching is driven by intolerance and similar across tyrosine kinase inhibitors and lines of treatment. HemaSphere 2022;6:Abstract S159."},{"key":"B50","series-title":"Leukemia","first-page":"966","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT,  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966\u2013984."},{"key":"B51","article-title":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia","author":"Shah NP","unstructured":"Shah NP, Bhatia R, Altman JK,  NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 2.2024. Accessed December 1, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B52","series-title":"Leuk Lymphoma","first-page":"1714","article-title":"Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"63","author":"Haddad F","year":"2022","unstructured":"Haddad F, Kantarjian H, Issa GC,  Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma 2022;63:1714\u20131717."},{"key":"B53","series-title":"Leuk Res","first-page":"58","article-title":"Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors","volume":"39","author":"Lipton JH","year":"2015","unstructured":"Lipton JH, Bryden P, Sidhu MK,  Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res 2015;39:58\u201364."},{"key":"B54","series-title":"Blood","first-page":"2042","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes J","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E,  Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 2021;138:2042\u20132050."},{"key":"B55","series-title":"Am J Hematol","first-page":"1619","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era","volume":"98","author":"Haddad FG","year":"2023","unstructured":"Haddad FG, Sasaki K, Bidikian A,  Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 2023;98:1619\u20131626."},{"key":"B56","series-title":"Blood","first-page":"393","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J,  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018;132:393\u2013404."},{"key":"B57","series-title":"Blood","first-page":"4361","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg RJ","year":"2009","unstructured":"Garg RJ, Kantarjian H, O\u2019Brien S,  The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114:4361\u20134368."},{"key":"B58","series-title":"Am J Hematol","first-page":"658","article-title":"The outcomes of patients with chronic myeloid leukemia treated with third-line BCR:ABL1 tyrosine kinase inhibitors","volume":"98","author":"Jabbour EJ","year":"2023","unstructured":"Jabbour EJ, Sasaki K, Haddad FG,  The outcomes of patients with chronic myeloid leukemia treated with third-line BCR:ABL1 tyrosine kinase inhibitors. Am J Hematol 2023;98:658\u2013665."},{"key":"B59","series-title":"Expert Opin Pharmacother","first-page":"751","article-title":"Ponatinib for the treatment of adult patients with resistant or intolerant chronic-phase chronic myeloid leukemia","volume":"23","author":"Haddad FG","year":"2022","unstructured":"Haddad FG, Issa GC, Jabbour E,  Ponatinib for the treatment of adult patients with resistant or intolerant chronic-phase chronic myeloid leukemia. Expert Opin Pharmacother 2022;23:751\u2013758."},{"key":"B60","series-title":"Leukemia","first-page":"617","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus A","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C,  Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 2023;37:617\u2013626."},{"key":"B61","series-title":"Oncologist","first-page":"386","article-title":"Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico","volume":"20","author":"Jaime-P\u00e9rez JC","year":"2015","unstructured":"Jaime-P\u00e9rez JC, Heredia-Salazar AC, Cant\u00fa-Rodr\u00edguez OG,  Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico. Oncologist 2015;20:386\u2013392."},{"key":"B62","series-title":"Bone Marrow Transplant","first-page":"23","article-title":"Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?","volume":"42","author":"Ruiz-Arg\u00fcelles GJ","year":"2008","unstructured":"Ruiz-Arg\u00fcelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML,  Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant 2008;42:23\u201328."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/1\/article-e237116.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/1\/article-e237116.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/1\/article-e237116.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T20:29:50Z","timestamp":1708720190000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/1\/article-e237116.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":62,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7116","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}